<DOC>
	<DOCNO>NCT00467051</DOCNO>
	<brief_summary>This phase II trial study well give combination chemotherapy work treat young patient recurrent resistant malignant germ cell tumor . Drugs use chemotherapy , paclitaxel , ifosfamide , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Recurrent Resistant Malignant Germ Cell Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate pediatric patient recurrent resistant malignant germ cell tumor ( GCT ) treat paclitaxel , ifosfamide , carboplatin . SECONDARY OBJECTIVES : I . Determine toxicity regimen patient . II . To Collect tissue tumor bank aid identification biological characteristic recurrent GCT . OUTLINE : This multicenter study . Patients receive paclitaxel IV 3 hour carboplatin IV 1 hour day 1 ifosfamide IV 1 hour day 1-5 . Beginning day 6 , patient receive filgrastim ( G-CSF ) subcutaneously IV daily blood count return normal . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Embryonal</mesh_term>
	<mesh_term>Endodermal Sinus Tumor</mesh_term>
	<mesh_term>Choriocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm ( original diagnosis ) extracranial germ cell tumor ( GCT ) contain 1 follow malignant element : Yolk sac tumor ( endodermal sinus tumor ) Choriocarcinoma Embryonal carcinoma Meets 1 follow disease criterion : Recurrent malignant disease Chemotherapyresistant disease Relapsed disease Disease refractory conventional therapy Measurable disease Must receive prior firstline chemotherapy regimen include cisplatin Patients tumor marker ( AFP and/or BHCG ) elevation alone bone scan finding alone eligible* Patients immature teratoma ( grade ) , germinoma , sexcord stromal tumor , recurrent GCT previously treat surgery alone eligible Karnofsky performance status ( PS ) 50100 % ( age &gt; 16 year ) OR Lansky PS 50100 % ( age ≤ 16 year ) OR ECOG PS 02 Life expectancy ≥ 8 week Absolute neutrophil count ≥ 750/mm³ Platelet count ≥ 75,000/mm³ ( transfusion independent ) Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine normal base age/gender , define follow : ≤ 0.4 mg/dL ( 1 month &lt; 6 month age ) ≤ 0.5 mg/dL ( 6 month &lt; 1 year age ) ≤ 0.6 mg/dL ( 1 &lt; 2 year age ) ≤ 0.8 mg/dL ( 2 &lt; 6 year age ) ≤ 1.0 mg/dL ( 6 &lt; 10 year age ) ≤ 1.2 mg/dL ( 10 &lt; 13 year age ) ≤ 1.4 mg/dL ( 13 ≥ 16 year age ) ( female ) ≤ 1.5 mg/dL ( 13 &lt; 16 year age ) ( male ) ≤ 1.7 mg/dL ( ≥ 16 year age ) ( male ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) age ALT &lt; 2.5 time ULN age Shortening fraction ≥ 27 % echocardiogram OR ejection fraction ≥ 50 % gate radionuclide study No dyspnea rest No exercise intolerance Pulse oximetry &gt; 94 % ( clinical indication determination ) Patients seizure disorder eligible provide nonenzyme induce anticonvulsant seizure well control No Central Nervous System ( CNS ) toxicity &gt; grade 2 No active graftversushost disease No allergy Cremophor EL castor oil Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent chemotherapy immunomodulating agent Recovered prior chemotherapy , immunotherapy , radiotherapy At least 1 week since prior growth factor ( 2 week pegfilgrastim ) At least 1 week since prior biologic therapy At least 2 week since prior myelosuppressive chemotherapy ( 4 week nitrosourea ) At least 2 week since prior local palliative radiotherapy ( i.e. , small port ) At least 6 month since prior craniospinal radiotherapy radiotherapy ≥ 50 % pelvis At least 6 week since prior substantial bone marrow radiotherapy At least 6 month since prior allogeneic stem cell transplantation Concurrent radiotherapy localize painful lesion allow provide least 1 measurable lesion irradiate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>